Completed PHASE3 INTERVENTIONAL 2-arm NCT00141453

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus

Sponsor: Daiichi Sankyo Co., Ltd.

Conditions Diabetic Nephropathy Proteinuria Type 2 Diabetes Mellitus

Interventions Placebo Tablets olmesartan medoxomil

Updated 9 times since 2017 Last updated: May 9, 2011 Started: Apr 30, 2003 Primary completion: Aug 31, 2008 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diabetic Nephropathy and Proteinuria and is currently completed. Daiichi Sankyo Co., Ltd. leads this study, which shows 9 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2024 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Sep 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Sep 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo Co., Ltd.

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong, China
• Tokyo, Japan